financetom
Business
financetom
/
Business
/
Intuit forecasts annual revenue above estimates on AI-driven financial tools
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Intuit forecasts annual revenue above estimates on AI-driven financial tools
Aug 27, 2024 6:20 AM

Aug 22 (Reuters) - Intuit forecast fiscal 2025

revenue above Wall Street estimates on Thursday, banking on

growing demand for its AI-driven financial management tools amid

recent price increases.

Shares of the Mountain View, California-based company rose

about 2% in extended trading as it also announced a new $3

billion repurchase authorization.

Intuit, known for products like TurboTax, Credit Karma, and

QuickBooks, has benefited from growing demand for its AI-powered

offerings, which provide personalized financial recommendations

and automation of specific tasks such as bookkeeping.

Earlier this month, Intuit implemented price increases

for QuickBooks, introducing new features to entice customers.

"Our momentum both in the first quarter and going into

next year is coming from our customer growth both with

QuickBooks Online and QuickBooks Advanced," Chief Executive

Sasan Goodarzi told Reuters in an interview on Thursday.

"We are adding almost 1,000 folks that are going to be

focused in several areas that are particularly around AI,"

Goodarzi said.

This AI-focused hiring comes on the heels of a significant

workforce restructuring. In July, Intuit announced plans to lay

off 10% of its workforce, or about 1,800 employees.

Intuit forecast fiscal 2025 revenue to be between $18.16

billion and $18.35 billion, the mid-point of which is slightly

above analysts' average estimate of $18.18 billion, according to

LSEG data.

The company expects annual adjusted profit per share to be

between $19.16 and $19.36, compared with average estimate of

$19.15.

The company also forecast first-quarter revenue growth to be

between 5% and 6%, below the average estimate of 13.1% growth,

as QuickBooks desktop products transitioned to a recurring

subscription model.

Intuit expects these changes to lower revenue in the first

quarter by about $160 million.

Revenue for the fourth quarter came in at $3.18 billion,

beating an estimate of $3.08 billion. Excluding items, it earned

$1.99 per share, compared with an estimated $1.84 per share.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Vecima Networks Announces First U.S.-made Electronics Equipment
Vecima Networks Announces First U.S.-made Electronics Equipment
Aug 20, 2024
08:00 AM EDT, 08/20/2024 (MT Newswires) -- Vecima Networks ( VNWTF ) on Tuesday said its first U.S.-made internet network electronics equipment will roll off the production line next week at MARA Technologies USA's Holly, Michigan manufacturing facility. The production is part of the Build America Buy America (BABA) requirements for the Broadband Equity Access and Deployment (BEAD) Program, the...
Exact Sciences's Multi-Cancer Early Detection Study Enrols First Patient
Exact Sciences's Multi-Cancer Early Detection Study Enrols First Patient
Aug 20, 2024
07:44 AM EDT, 08/20/2024 (MT Newswires) -- Exact Sciences ( EXAS ) said on Tuesday the first patient had joined its multi-cancer early detection falcon registry study at Baylor Scott & White, its primary study site in Texas. The company said the study, involving up to 25,000 patients, would assess the performance, experience, and impact of multi-cancer early detection testing...
Tonix Pharmaceuticals Begins Phase 2 Trial of Cocaine Intoxication Treatment
Tonix Pharmaceuticals Begins Phase 2 Trial of Cocaine Intoxication Treatment
Aug 20, 2024
07:58 AM EDT, 08/20/2024 (MT Newswires) -- Tonix Pharmaceuticals ( TNXP ) said Tuesday its first patient was dosed in its phase 2, single-blind, placebo-controlled trial of TNX-1300 for treating acute cocaine intoxication in emergency departments. TNX-1300 is a recombinant enzyme that degrades and metabolizes cocaine in cocaine users. The trial will assess the safety and efficacy of a single...
Market Chatter: Walt Disney, Reliance Face India Antitrust Scrutiny Over Cricket
Market Chatter: Walt Disney, Reliance Face India Antitrust Scrutiny Over Cricket
Aug 20, 2024
08:05 AM EDT, 08/20/2024 (MT Newswires) -- India's antitrust watchdog has concluded preliminarily that the $8.5 billion merger of Walt Disney's ( DIS ) India assets and Reliance MediaWorks hurts competition, Reuters reported Tuesday, citing unnamed sources. The Competition Commission of India considers the two companies' potential domination of cricket broadcast rights the main obstacle, the report said. The watchdog...
Copyright 2023-2025 - www.financetom.com All Rights Reserved